1. Home
  2. MDXG vs SII Comparison

MDXG vs SII Comparison

Compare MDXG & SII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDXG
  • SII
  • Stock Information
  • Founded
  • MDXG 2006
  • SII 2008
  • Country
  • MDXG United States
  • SII Canada
  • Employees
  • MDXG N/A
  • SII N/A
  • Industry
  • MDXG Biotechnology: Pharmaceutical Preparations
  • SII Finance: Consumer Services
  • Sector
  • MDXG Health Care
  • SII Finance
  • Exchange
  • MDXG Nasdaq
  • SII Nasdaq
  • Market Cap
  • MDXG 877.4M
  • SII 1.1B
  • IPO Year
  • MDXG N/A
  • SII N/A
  • Fundamental
  • Price
  • MDXG $6.34
  • SII $69.82
  • Analyst Decision
  • MDXG Strong Buy
  • SII
  • Analyst Count
  • MDXG 2
  • SII 0
  • Target Price
  • MDXG $12.50
  • SII N/A
  • AVG Volume (30 Days)
  • MDXG 628.7K
  • SII 167.6K
  • Earning Date
  • MDXG 07-30-2025
  • SII 08-06-2025
  • Dividend Yield
  • MDXG N/A
  • SII 1.65%
  • EPS Growth
  • MDXG N/A
  • SII 10.23
  • EPS
  • MDXG 0.27
  • SII 1.93
  • Revenue
  • MDXG $352,375,000.00
  • SII $180,474,000.00
  • Revenue This Year
  • MDXG $9.55
  • SII $0.57
  • Revenue Next Year
  • MDXG $11.43
  • SII $8.89
  • P/E Ratio
  • MDXG $23.48
  • SII $36.11
  • Revenue Growth
  • MDXG 5.34
  • SII 17.97
  • 52 Week Low
  • MDXG $5.47
  • SII $38.41
  • 52 Week High
  • MDXG $10.14
  • SII $69.98
  • Technical
  • Relative Strength Index (RSI)
  • MDXG 53.33
  • SII 78.43
  • Support Level
  • MDXG $5.86
  • SII $66.94
  • Resistance Level
  • MDXG $6.42
  • SII $69.54
  • Average True Range (ATR)
  • MDXG 0.21
  • SII 1.56
  • MACD
  • MDXG 0.07
  • SII 0.11
  • Stochastic Oscillator
  • MDXG 87.30
  • SII 99.18

About MDXG MiMedx Group Inc

MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.

About SII Sprott Inc.

Sprott Inc is an alternative asset manager. The company has four reportable segments: Exchange Listed Products, which derives key revenue, and includes management services to the company's closed-end physical trusts and exchange-traded funds, both of which are actively traded on public securities exchanges; Managed equities segment provides asset management and sub-advisory services to the company's branded funds, fixed-term LPs and managed accounts; Private strategies which provide lending and streaming activities through limited partnership vehicles; and the Corporate segment which provides capital, balance sheet management and enterprise shared services to the company's subsidiaries. Geographically, it derives key revenue from Canada, followed by the United States.

Share on Social Networks: